Studies from our lab and others in T47D and MCF-7 breast cancer cells have shown that the PI3K/AKT and RAF/MEK/ERK pathways are activated in parallel following PRL treatment, which leads to profound cell proliferation and survival (69, 70). Here, MAP2K7 is linked to breast cancer.